Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Drug Repurposing Project To Kick Off In Q1 2020

New Uses Should Have Important Public Health Benefits

Executive Summary

Finding new uses for older drugs is the objective of a European repurposing project that will begin in early 2020. 

You may also be interested in...



UK Set To Launch Drug Repurposing Project

Licensing new uses of existing medicines has several benefits over off-label use, such as offering assurances that the indication is evidence based and subject to an ongoing safety monitoring program, according to a new report.

UK Set To Launch Drug Repurposing Project

Licensing new uses of existing medicines has several benefits over off-label use, such as offering assurances that the indication is evidence based and subject to an ongoing safety monitoring program, according to a new report.

EU ‘Repurposing’ Project Plans Pilot Phase

A dedicated working group is taking forward a drug repurposing proposal originally devised by European industry bodies, with a view to determining the procedures to be used and running a pilot project with individual drug candidates.

Topics

UsernamePublicRestriction

Register

PS141426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel